145 related articles for article (PubMed ID: 34893792)
1. Metformin Treatment Among Men With Diabetes and the Risk of Prostate Cancer: A Population-Based Historical Cohort Study.
Freedman LS; Agay N; Farmer R; Murad H; Olmer L; Dankner R
Am J Epidemiol; 2022 Mar; 191(4):626-635. PubMed ID: 34893792
[TBL] [Abstract][Full Text] [Related]
2. Metformin Treatment and Cancer Risk: Cox Regression Analysis, With Time-Dependent Covariates, of 320,000 Persons With Incident Diabetes Mellitus.
Dankner R; Agay N; Olmer L; Murad H; Keinan Boker L; Balicer RD; Freedman LS
Am J Epidemiol; 2019 Oct; 188(10):1794-1800. PubMed ID: 31269196
[TBL] [Abstract][Full Text] [Related]
3. Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study.
Chen CB; Eurich DT; Majumdar SR; Johnson JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):122-126. PubMed ID: 28071672
[TBL] [Abstract][Full Text] [Related]
4. Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models.
Farmer RE; Ford D; Mathur R; Chaturvedi N; Kaplan R; Smeeth L; Bhaskaran K
Int J Epidemiol; 2019 Apr; 48(2):527-537. PubMed ID: 30753459
[TBL] [Abstract][Full Text] [Related]
5. Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
Au Yeung SL; Schooling CM
BMJ Open Diabetes Res Care; 2019; 7(1):e000872. PubMed ID: 31908803
[TBL] [Abstract][Full Text] [Related]
6. Sulfonylurea and Cancer Risk Among Patients With Type 2 Diabetes: A Population-Based Cohort Study.
Zhao H; Liu Z; Zhuo L; Shen P; Lin H; Sun Y; Zhan S
Front Endocrinol (Lausanne); 2022; 13():874344. PubMed ID: 35846337
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.
Häggström C; Van Hemelrijck M; Zethelius B; Robinson D; Grundmark B; Holmberg L; Gudbjörnsdottir S; Garmo H; Stattin P
Int J Cancer; 2017 Feb; 140(3):611-617. PubMed ID: 27770555
[TBL] [Abstract][Full Text] [Related]
8. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
[TBL] [Abstract][Full Text] [Related]
9. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
10. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
Orkaby AR; Cho K; Cormack J; Gagnon DR; Driver JA
Neurology; 2017 Oct; 89(18):1877-1885. PubMed ID: 28954880
[TBL] [Abstract][Full Text] [Related]
11. Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer.
Raval AD; Mattes MD; Madhavan S; Pan X; Wei W; Sambamoorthi U
J Diabetes Res; 2016; 2016():2656814. PubMed ID: 27547763
[TBL] [Abstract][Full Text] [Related]
12. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records.
Doran W; Tunnicliffe L; Muzambi R; Rentsch CT; Bhaskaran K; Smeeth L; Brayne C; Williams DM; Chaturvedi N; Eastwood SV; Dunachie SJ; Mathur R; Warren-Gash C
BMJ Open Diabetes Res Care; 2024 Jan; 12(1):. PubMed ID: 38272537
[TBL] [Abstract][Full Text] [Related]
13. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
[TBL] [Abstract][Full Text] [Related]
14. Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.
Wang CP; Lehman DM; Lam YF; Kuhn JG; Mahalingam D; Weitman S; Lorenzo C; Downs JR; Stuart EA; Hernandez J; Thompson IM; Ramirez AG
Cancer Prev Res (Phila); 2016 Oct; 9(10):779-787. PubMed ID: 27026681
[TBL] [Abstract][Full Text] [Related]
15. Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
Kuo YJ; Sung FC; Hsieh PF; Chang HP; Wu KL; Wu HC
Cancer Med; 2019 May; 8(5):2514-2523. PubMed ID: 30968600
[TBL] [Abstract][Full Text] [Related]
16. Association between metformin use and risk of prostate cancer and its grade.
Margel D; Urbach D; Lipscombe LL; Bell CM; Kulkarni G; Austin PC; Fleshner N
J Natl Cancer Inst; 2013 Aug; 105(15):1123-31. PubMed ID: 23853056
[TBL] [Abstract][Full Text] [Related]
17. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Bowker SL; Lin M; Eurich DT; Johnson JA
Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
[TBL] [Abstract][Full Text] [Related]
18. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
Kuan YC; Huang KW; Lin CL; Hu CJ; Kao CH
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):77-83. PubMed ID: 28583443
[TBL] [Abstract][Full Text] [Related]
19. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort.
Vihervuori VJ; Talala K; Taari K; Lahtela J; Tammela TLJ; Auvinen A; Raittinen P; Murtola TJ
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):982-989. PubMed ID: 33653815
[TBL] [Abstract][Full Text] [Related]
20. Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer.
Linkeviciute-Ulinskiene D; Patasius A; Kincius M; Zabuliene L; Smailyte G
Scand J Urol; 2020 Oct; 54(5):401-407. PubMed ID: 32748714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
